Short biography and research interests:

Zbigniew Darzynkiewicz, M.D., Ph.D., 
is the Director of the Brander Cancer Research Institute at the New York Medical College and the Professor of Medicine and Pathology at the same College. Formerly, Dr. Darzynkiewicz was the Professor of Cell Biology and Genetics at Cornell University Medical School, a Member of the Sloan-Kettering Institute for Cancer Research, the Head of the Experimental Cell Research Laboratory, and the Director of the Flow Cytometry Core Facility Network, all at the Sloan-Kettering Institute, New York. 

Dr. Darzynkiewicz is the Editor of the Experimental Cell Research and Cell Proliferation and a Member of the Editorial Boards of 10 other scientific journals. He is the past President of The Cell Kinetics Society and also past President of the International Society for Analytical Cytology (ISAC; >2000 members from over 60 countries). 

Dr. Darzynkiewicz's research concentrates on cell biology with particular focus on cancer cell growth and the regulatory mechanisms associated with cell growth and progression through the cell cycle. He has developed several techniques that have world-wide application, to analyze metabolic parameters of the cell related to cell cycle kinetics, cell sensitivity to anti-tumor drugs and apoptosis. He was a recipient of the prestigious MERIT grant award from the National Institute of Health (NIH). Since 1972 his research has been continuously supported by the grants from NIH and other agencies. He was also a recipient of a grant from NASA to develop new technologies for cell staining and analysis applicable to the micro-gravity conditions of the Space Station. 

Dr. Darzynkiewicz has authored over 400 original publications and over 75 chapters and reviews in books devoted to the subject of cell growth, regulation of the cell cycle and apoptosis, and has authored and/or edited 11 books. He holds five US patents, several are pending. His publications have been cited over 10.000 times in the scientific literature. He consults several pharmaceutical companies and is on the Board of Scientific Advisors of the Alfacell Co. (Bloomfield, N.J.) and PharmaSeq Co. (Princeton, N.J) 

Dr. Darzynkiewicz received his M.D. (with the highest honors) in 1960 and his Ph.D. in 1966 from the Medical School of Warsaw, Warsaw, Poland. He completed his post-graduate studies at the State University of New York at Buffalo and the Medical Nobel Institute of Karolinska Institute, Stockholm, Sweden. Since 1974, he has been associated with the Sloan-Kettering Institute for Cancer Research, and since 1990, he has been with New York Medical College, Valhalla, New York.